
Liquidity, historical trends, and peer comparisons.
According to Damora Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 19.73. This represents a change of 33.94% compared to the average of 14.73 of the last 4 quarters.
The mean historical Current Ratio of Damora Therapeutics, Inc. over the last ten years is 13.59. The current 19.73 Current Ratio has changed 45.22% with respect to the historical average. Over the past ten years (40 quarters), DMRA's Current Ratio was at its highest in in the December 2020 quarter at 30.42. The Current Ratio was at its lowest in in the September 2019 quarter at 0.
Average
13.59
Median
10.42
Minimum
5.75
Maximum
30.42
Discovering the peaks and valleys of Damora Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 329.93%
Maximum Annual Current Ratio = 30.42
Minimum Annual Increase = -76.25%
Minimum Annual Current Ratio = 5.75
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 12.98 | -7.74% |
| 2024 | 14.07 | 123.02% |
| 2023 | 6.31 | 9.62% |
| 2022 | 5.75 | -76.25% |
| 2021 | 24.23 | -20.34% |
| 2020 | 30.42 | 329.93% |
| 2019 | 7.07 | -10.07% |
The current Current Ratio of Damora Therapeutics, Inc. (DMRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
11.12
5-year avg
12.67
10-year avg
13.59
Damora Therapeutics, Inc.’s Current Ratio is greater than Rigel Pharmaceuticals, Inc. (1.95), less than Hemab Therapeutics Holdings, Inc. Common Stock (35.85), greater than Genmab A/S (2.46), greater than Geron Corporation (6.92), greater than Incyte Corporation (4.66), less than Keros Therapeutics, Inc. (21.96), less than Disc Medicine, Inc. (24.14), greater than uniQure N.V. (10.01),
| Company | Current Ratio | Market cap |
|---|---|---|
| 1.95 | $899.06M | |
| 35.85 | $1.61B | |
| 2.46 | $26.93B | |
| 6.92 | $719.57M | |
| 4.66 | $23.45B | |
| 21.96 | $223.65M | |
| 24.14 | $2.86B | |
| 10.01 | $1.56B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Damora Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Damora Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Damora Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Damora Therapeutics, Inc. (DMRA)?
What is the highest Current Ratio for Damora Therapeutics, Inc. (DMRA)?
What is the 3-year average Current Ratio for Damora Therapeutics, Inc. (DMRA)?
What is the 5-year average Current Ratio for Damora Therapeutics, Inc. (DMRA)?
How does the current Current Ratio for Damora Therapeutics, Inc. (DMRA) compare to its historical average?